Next Article in Journal
Involvement of COUP-TFs in Cancer Progression
Next Article in Special Issue
Growth Factor Mediated Signaling in Pancreatic Pathogenesis
Previous Article in Journal
Ras Isoprenylation and pAkt Inhibition by Zoledronic Acid and Fluvastatin Enhances Paclitaxel Activity in T24 Bladder Cancer Cells
Previous Article in Special Issue
Palliative Interventional and Surgical Therapy for Unresectable Pancreatic Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(1), 675-699;

Treatment of Pancreatic Cancer: What Can We Really Predict Today?

Gastrointestinal Cancer Unit, Department of Gastroenterology, Hôpital Erasme, Université Libre de Bruxelles, 808 route de Lennik, B-1070 Brussels, Belgium
EA4340 "Epidémiologie et oncogènes des tumeurs digestives", Université de Versailles, St-Quentin-en-Yvelines, France
Department of Gastroenterology, Hôpital Pitié Salpêtrière, Assistance Publique—Hôpitaux de Paris, France
Author to whom correspondence should be addressed.
Received: 3 December 2010 / Revised: 24 January 2011 / Accepted: 4 February 2011 / Published: 17 February 2011
(This article belongs to the Special Issue Pancreatic Cancer)
View Full-Text   |   Download PDF [250 KB, uploaded 17 February 2011]


Managing pancreatic cancer remains a big challenge due to its worse course and prognosis. However, therapeutic options and multimodal strategies are increasing nowadays, including new agents, new regimens and chemoradiation. Recently, the FOLFIRINOX regimen has been reported to be more active than gemcitabine in selected metastatic patients. In this setting, it will be of utmost interest to guide our therapeutic choice not only on clinical and pathological findings, but also on specific biomarkers that will predict tumor behavior and patient outcome (prognostic markers), and benefit from specific agents or regimens (predictive markers). In the near future, we will have to build both our therapeutic interventions and our clinical research based on an accurate patients’ clinical selection and on biomolecular markers. In this review, we aimed to highlight and discuss some of the recent results reported on biomarkers in pancreatic cancer that may predict, i.e., preferential metastatic diffusion after surgery, like CXCR4, or predict gemcitabine efficacy in an adjuvant setting as well as in advanced disease, like hENT1. An important effort for translational research in pancreatic cancer research is thus required to validate such markers, while some important questions concerning tissue availability and processing, methodology of analysis, and design of future prospective trials, need to be addressed. View Full-Text
Keywords: pancreatic; cancer-personalized; therapy-predictive; biomarkers-gemcitabine; nucleoside; transporters-CXCR4-SMAD4-hENT1 pancreatic; cancer-personalized; therapy-predictive; biomarkers-gemcitabine; nucleoside; transporters-CXCR4-SMAD4-hENT1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Bachet, J.-B.; Marechal, R.; Van Laethem, J.-L. Treatment of Pancreatic Cancer: What Can We Really Predict Today? Cancers 2011, 3, 675-699.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top